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Introduction
Multipotent stem cells extracted from many adult tissues 
are an attractive stem cell resource for the replacement of 
damaged tissues in regenerative medicine and have been 
identifi ed in many organs and tissues, including bone 
marrow, peripheral blood, fat, skeletal muscle, brain, 
skin, cornea, heart, gut, liver, ovarian epithelium, and 
testis. Multipotent stem cells are all defi ned as undiff er-
en tiated cells, are able to self-renew with a high prolifera-
tive rate, and have the potential to diff erentiate into 
specialized cells with specifi c functions [1]. Unlike pluri-
potent embryonic stem (ES) cells, multipotent stem cells 
are usually restricted to a particular lineage (mesodermal, 
endodermal, or ectodermal) but have the potential to 
diff erentiate into distinct somatic cell types with appro-
priate stimulation (Figure  1). Two main advantages for 
their use in clinical applications are that they avoid some 
ethical issues associated with pluripotent ES cells, 
resulting in a more timely approval for research and 
thera peutic use, and that adult stem cells and tissues 
derived from them are currently believed to be less likely 
to initiate rejection after transplantation.
Although human adult stem cells represent a promising 
tool for applying new clinical concepts in support of 
cellular therapy, many aspects remain to be explored in 
order to guarantee appropriate quality assurance and 
control of these cells, such as avoiding inappropriate gene 
expression in transplanted cells or the undesirable traits 
of tumorigenesis. Gene expression potential in stem cell 
renewal and diff erentiation could be regulated by epi-
genetic processes that confer a specifi c chromatin confor-
mation of the genome, of which DNA methylation is the 
best characterized (Figure 1) [2]. DNA methylation, the 
addition of a methyl group to the carbon 5 of the cytosine 
into CpG contexts, is known to be an essential process in 
development and cellular diff erentiation [3]. It is involved 
in gene regulation of housekeeping and tissue-type genes, 
silencing of one allele of imprinted genes, and compensa-
tion of the extra copy of the X chromosome in females. It 
acts as a defense mechanism, preventing genomic in-
stability due to transposon movements or insertion of 
endoparasitic sequences in the genome [4]. It must be 
pointed out that DNA methylation does not work alone 
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after treatment with demethylating agents and by 
considering the evidence provided by reprogramming 
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As a consequence, in a clinical setting, caution should 
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derivatives in regenerative medicine and appropriate 
tests should be applied to ensure the integrity of the 
genome and epigenome.
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in controlling chromatin conformation since histone 
modifi cations and non-coding RNA regulation also 
collaborate in its control. So, we must consider the 
existence of an ‘epigenetic code’ in which several epi-
genetic factors act in a gradual and progressive manner 
for controlling chromatin structure.
Currently, much attention is being paid to the eff ects of 
CpG methylation on stemness and diff erentiation. Th e 
fi rst piece of evidence came from the observation that 
important genes for the maintenance of ES cells, such as 
Oct4 and Nanog genes, are usually hypomethylated when 
activated but became hypermethylated during diff eren-
tiation [5,6]. Knowledge of the genome-wide contribution 
of CpG methylation to stem cell maintenance and diff er-
entiation has increased in recent years, mainly because of 
the development of technical approaches for assessing 
epigenetic factors. High-throughput strategies demon-
strate that human ES cells have a unique CpG 
methy lation signature that, in combination with histone 
modi fi  cations, drives stem cell diff erentiation through 
the restriction of the developmental potential of 
progenitor cells [7,8]. In comparison with the broad-
ranging infor mation obtained from ES cells, the role of 
CpG methy lation in regulating diff erentiation of adult 
stem cells has been less extensively examined. In this 
review, we consider the reported evidence of how the 
developmental potential of adult stem cells could be 
restricted by the gain of DNA methylation of self-renewal 
genes (prevent ing the undiff erentiated features of stem 
cells in adult somatic cells) and the DNA methylation-
dependent control of tissue-specifi c genes (abolishing the 
risks of lineage-unrelated gene expression). Th e 
opportunities that this presents for manipulating the 
epigenome by means of pharmacological treatments and 
its consequences for stem cell diff erentiation and repro-
gram ming will be analyzed.
Figure 1. Lineage restriction of human developmental potency. Totipotent cells at the morula stage have the ability to self-renew and 
diff erentiate into all of the cell types of an organism, including extraembryonic tissues. Pluripotent cells – for example, in vitro embryonic stem (ES) 
cells established at the blastocyst stage and primordial germ cells (PGCs) from the embryo – lose the capacity to form extraembryonic tissues like 
placenta. Restriction of diff erentiation is imposed during normal development, going from multipotent stem cells (SCs), which can give rise to cells 
from multiple but not all lineages, to the well-defi ned characteristics of a somatic diff erentiated cell (unipotent). Specifi c chromatin patterns and 
epigenetic marks can be observed during human development since they are responsible for controlling transcriptional activation and repression 
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DNA methylation, global chromatin context, and 
stemness
It is important to point out that the relationship between 
promoter DNA methylation and promoter activity 
depends on the CpG content of the promoters: high CpG 
promoters (HCPs), intermediate CpG promoters, or low 
CpG promoters (LCPs). In ES cells and multipotent 
progenitor cells, HCP promoters are characterized by 
low DNA methylation levels, whereas LCP promoters are 
enriched in DNA methylation [6,8,9] (Figure 2). Further-
more, specifi c histone modifi cations (that is, H3K4me3 
and H3K27me3) in HCPs appear to be more decisive for 
expression of the corresponding genes and suggest a 
degree of protection from DNA methylation [10] (Figure 2). 
Conversely, methylated LCP promoters are depleted of 
bivalent histone marks and are mostly repressed in ES 
cells [6,8,9] (Figure  2). It is suggested that silencing of 
pluripotency-related genes occurs by means of CpG 
promoter hypermethylation, whereas gain of diff erentia-
tion features is defi ned by gene regulation of Polycomb 
targets [8].
Specifi c epigenetic features at a global level also under-
pin the pluripotency of ES cells. Recent studies have 
demonstrated that ES cell chromatin is in a highly 
dynamic state with global DNA hypomethylation and a 
general abundance of transcriptionally active chromatin 
marks such as H3K4me3 and acetylation of histone H4, 
which is refl ected in the relatively decondensed 
chromatin of ES cells [2,11]. Th is global lack of DNA 
methylation in stem cells could be associated with the 
ability of such cells to activate a wide range of cell type-
specifi c genes during the diff erentiation pro grams [2]. It 
must not be forgotten that DNA methylation and histone 
modifi cations do not work alone and that the epigenetic 
inactivation of diff erentiation-specifi c genes in stem cells 
(that is, Hox and Pax family of genes) is usually repressed 
by alternative chromatin remodeling factors, such as 
Polycomb proteins [11,12]. Consequently, further study 
of the interplay of all of the chromatin regulators is 
essential for understanding the dynamism of trans crip-
tional control during stem cell renewal and 
diff erentiation.
DNA methylation-dependent regulation of genes 
associated with self-renewal of stem cells
It has been widely reported that maintenance of the 
pluripotency state is conferred by a set of development-
associated transcription factors – such as OCT4, 
NANOG, and SOX2 – that occupy promoters of active 
genes associated with self-renewal [13,14]. Expression of 
the aforementioned transcription regulators is usually 
controlled by CpG promoter methylation, and diff eren-
tiation of ES cells is accomplished by partial or full 
methylation of pluripotency-associated genes, resulting 
in their downregulation [6,15-17]. Th e opposite asso-
ciation has been found in the reprogramming of induced 
pluripotent stem (iPS) cells from diff erentiated cells, in 
which unmethylated active promoters of ES cell-specifi c 
genes were described [18] (Figure  2). Despite the con-
sider able information about silencing of pluripotency ES 
genes during diff erentiation, very little is known about 
the epigenetic control of genes associated with self-
renewal and maintenance of multipotent adult stem cells. 
In adipose-derived stem cells (ASCs) and mesenchymal 
stem cells from bone marrow (BM-MSCs), OCT4 is 
silenced by promoter hypermethylation, whereas Nanog 
and Sox2 are unmethylated despite the repressed state of 
the genes [19]. Th e same patterns of methylation were 
found in diff erentiated fi broblasts and keratinocytes [19]. 
It seems that, whereas Oct4 regulation is strongly in-
fl uenced by CpG promoter hypermethylation, the control 
of Nanog and Sox2 expression could be due to other 
repressive mechanisms such as histone modifi cation 
patterns [19]. Enrichment of H3K27me3 and H3K9me3 
and reduction of H3K79me3 have been described in the 
Nanog and Sox2 promoters of ASCs and diff erentiated 
cells but not in pluripotent cells [20]. Th ese results 
demonstrate that the transcriptional repression mecha-
nisms could vary depending on the gene and the state of 
cellular diff erentiation (that is, multipotency versus 
diff er en tiation) [19] and could constitute a mechanism 
for preventing aberrant reactivation of pluripotency and 
minimizing the risk of de-diff erentiation [21]. In line with 
this hypothesis, ES cells with genetic mutations of DNA 
methyltransferase result in rapid apoptosis-mediated cell 
death [22,23].
Th e promoter methylation status of additional stem 
cell-determining genes for self-renewal (not exclusively 
markers of pluripotency) has also been investigated [24]. 
Silencing of the mesodermal transcription factor 
Brachyury gene during diff erentiation from BM-MSCs to 
mesodermal lineages involves hypermethylation of its 
promoter but not changes in promoter hypermethylation 
of genes such as LIN28, NESTIN, or ZFP42. Th is could be 
associated with changes of expression during diff eren-
tiation of BM-MSCs [24]. Currently, we have a limited 
understanding of how multipotency is established and 
maintained in adult stem cells, and it would be very 
interesting to study the CpG promoter methylation status 
of transcription factors that confer multipotency on adult 
stem cells beyond the traditional role of pluripotency 
genes such as Oct4, Nanog, and Sox2.
Specifi c CpG methylation during diff erentiation of 
multipotent stem cells
Cellular diff erentiation is determined by a loss of 
proliferation potential and a gain of cell-type identity. 
Th is reduction of developmental potential could be 
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restricted by epigenetic modifi cations that prevent the 
risks of lineage-unrelated gene expression or undiff er-
entiated features of stem cells in adult cells [3]. However, 
the role of specifi c promoter methylation in controlling 
gene diff erentiation remains a matter of controversy. On 
one hand, there are some clues in favor of the hypothesis 
that cell type-specifi c patterns of DNA methylation 
infl uence cell type-specifi c gene expression and, by 
extension, cellular diff erentiation. For example, promoter 
methylation of SERPINB5 is inversely correlated with the 
unique expression of SERPINB5 in epithelial cells [25], 
and the rSPHK1 and hSLC6A8 promoter hypermethy-
lation associated with gene silencing in specifi c tissues 
allows expression in unmethylated brain tissue only 
[26,27]. On the other hand, genome-wide analysis of CpG 
methylation changes during the conversion of human 
pluripotent/multipotent stem cells into diff erentiated 
somatic cells reveals small changes in DNA methylation 
at promoter regions [8,9,28-30]. For example, lineage 
commitment of neural progenitor cells into terminally 
diff erentiated neurons occurs with a very moderate 
number of promoter DNA hypermethylated genes as 
cells diff erentiate [8]. Further work is needed to test 
whether these weak associations between gene repression 
and CpG hypermethylation during diff erentiation are due 
to limitations of the analytical techniques or to the 
existence of additional methylation-independent regula-
tory mechanisms.
Does CpG methylation of multipotent stem cells 
restrict lineage specifi cation?
One of the main features of adult stem cells is their 
multipotency (that is, their ability to diff erentiate into a 
number of cell types), but, in contrast to pluripotent cells, 
they are restricted to those of a closely related family of 
cells. For example, BM-MSCs primarily form mesodermal-
specifi c cell types such as chondrocytes, myocytes, 
adipo cytes, or osteoblasts [1]. However, we should 
remember that, given the information collected in recent 
years, this could be a very general statement, and there is 
some evidence to suggest that lineage restriction could be 
more permissive. For instance, BM-MSCs could be diff er-
en tiated into cells of all three germ layers and generate 
tissues such as osteocytes (mesoderm), hepatocytes 
(endoderm), or neurons (ectoderm) [31-33]. Multipotent 
cells isolated from diff erent tissues have common in vitro 
phenotypic and functional characteristics (for example, 
MSCs share fi broblast-like morphology, plastic adher-
ence, proliferation ability, and clonogenicity) but diff er in 
the expression of specifi c lineage markers (for example, 
ASCs and BM-MSCs diff er in the expression of the 
surface markers CD90, CD105, CD106, and adhesion 
molecules [34,35] and in their diff erentiation potential). 
Since gene expression in adult stem cells is regulated by 
epigenetic processes, a question arises: is the diff er en-
tiation potential in adult stem cells predicted by DNA 
methylation of specifi c lineage promoters? Th ere is some 
evidence in favor of a diff erentiation restriction imposed 
by promoter hypermethylation in progenitor stem cell 
states, whereas promoter hypomethylation does not have 
any predictive value with respect to diff erentiation 
potential [35,36]. Characterization of DNA methylation 
profi les of all human RefSeq promoters in mesenchymal 
adult stem cells from various origins, including adipose, 
hematopoietic, and neural progenitors and muscle tissue, 
shows that the majority of the lineage-specifi c genes are 
hypomethylated even if the progenitor is not able to 
diff erentiate into this specifi c lineage [10]. Th ere are 
some examples of epigenetic silencing associated with 
restriction to diff erentiation: endothelial markers such as 
CD31 and CD144 are strongly methylated in ASCs that 
show very limited capacity for endothelial diff erentiation 
[36] or osteogenic and adipogenic restriction of C2C12 
myoblast cell line diff erentiation [37]. Furthermore, the 
restriction for diff erentiation in specifi c programs im-
posed by means of DNA methylation is established early 
in development, in the progenitor state, and persists after 
diff erentiation, as most of the hypermethylated 
promoters in undiff erentiated cells remain hypermethy-
lated in somatic cells [10,37]. Th is is in agreement with 
the low level of de novo methylation described after 
diff erentiation of adult stem cells [8,9]. Results lead to the 
conclusion that the diff erentiation restriction associated 
with promoter hypermethylation clearly diff ers between 
pluripotent and multipotent cells: lineage-specifi c 
promoters are mostly hypermethylated in ES cells [6] in 
contrast to the low-percentage hypermethylation found 
in MSCs [35].
Treatment with demethylating agents results in 
spontaneous diff erentiation
Th e involvement of DNA methylation in controlling the 
diff erentiation potential of stem cells has been supported 
by several reports of spontaneous diff erentiation after 
treatment with demethylating agents (Table 1). For exam-
ple, the use of 5-aza-2’-deoxycytidine (5-ADC) promotes 
diff erentiation of ASCs into cardiac myogenic cells [38]. 
Pretreatment with 5-ADC also drives the osteogenic 
diff erentiation of BM-MSCs by enhancing the expression 
of osteogenic genes (such as Dlx5) associated with 
demethylation of its CpG shore [39,40]. However, we 
must remember that DNA methylation is just one com-
po nent of the epigenetic machinery and that removing 
DNA methy lation is often insuffi  cient to reactivate gene 
expression (Table  1). Treatments with the histone de-
acetylase (HDAC) inhibitor trichostatin A (TSA) enhance 
chon dro genic diff erentiation of BM-MSCs accomplished 
by increased expression of Sox9 [41]. Similarly, neural 
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induction was achieved when multipotent stem cells 
were exposed to TSA simultaneously with 5-ADC [42]. 
Furthermore, the eff ects of treatments with HDAC 
inhibitors are known to alter DNA methylation levels 
[41,42]. Additional evidence for the role of epigenetic 
control in diff erentiation comes from the functional 
consequences of defects in enzymes of the epigenetic 
machinery. For example, recovery of the expression of a 
defect in a histone modifi er (NSD1) suppresses cell 
growth and increases the diff erentiation of neuro blas-
toma cell lines [43]. Recovery of epigenetic patterns, by 
treatment with epigenetic drugs or by genetic models, 
highlights the potential of epigenetic modifi ers, possibly 
in combination with other factors, to enhance the ability 
of multipotent stem cells to form functional diff erentiated 
cells and has signifi cant therapeutic implications. Some 
consistent lines of evidence support this therapeutic 
application since epigenetic drugs, among them de-
methy lating agents, have shown signifi cant antitumor 
activity and the US Food and Drug Administration has 
approved the use of some of them to treat patients with 
cancer [4]. Indeed, new HDAC inhibitors (that is, 
romidepsin, belinostat, or givinostat) that are currently 
being tested in clinical trials for anticancer therapy [44] 
must also be considered as candidate molecules for 
assessing stem cell diff eren tiation. Further understanding 
of the epigenetic regula tion of tissue-specifi c genes along 
with the development of additional specifi c epigenetic 
drugs may hold the key to our ability to reset the 
epigenome successfully during stem cell diff erentiation.
Concluding remarks
It is clear that cell diff erentiation of multipotent stem 
cells is a result of a complex and dynamic network of 
transcriptional regulators, among them epigenetic factors 
that play a central role through controlling the expression/
repression of tissue-specifi c genes and multipotency-
related genes. However, it is not currently possible to 
manipulate cell diff erentiation even if we consider all of 
the genetic and epigenetic knowledge available for a 
specifi c lineage commitment. For example, epigenetic 
treatments may have a pleiotropic eff ect on the diff er-
entiation of stem cells, depending on multiple factors, 
mainly the origin of the precursor cell and environment 
conditions (presence of growth factors, transcriptional 
regulators, and so on) [39,41,45], suggesting that global 
epigenetic modifi cations, though necessary, are not suffi  -
cient to transdiff erentiate by themselves [46]. Th ese fi nd-
ings underline the necessity of evaluating in more detail 
the importance of epigenetic chromatin remodel ing for 
establishing and maintaining stemness or, on the other 
hand, initiating a diff erentiation program. Th e repro-
gram ming of somatic cells provides a new oppor tunity to 
study the contribution of epigenetics to diff erentiation. A 
mature cell can be converted into a pluripotent state by 
three experimental approaches: somatic nuclear transfer 
into enucleated oocytes, the in vitro application of a 
defi ned set of transcription factors creating iPS cells, or 
fusing ES cells with somatic cells to generate hetero-
karyons and hybrids [47]. Epigenetic rearrange ments are 
observed independently of the technique [48,49]. In fact, 
Table 1. Eff ects on diff erentiation potential of multipotent/pluripotent stem cells after treatment with epigenetic drugs
Stem cell classifi cation Epigenetic drug Diff erentiation after treatment Reference
Multipotent stem cells   
 Adipose-derived stem cells 5-aza-2’-deoxycytidine Cardiomyocytes [38]
 Adipose-derived stem cells 5-aza-2’-deoxycytidine; trichostatin A Cardiomyocytes [57]
 Bone marrow mesenchymal stem cells 5-aza-2’-deoxycytidine Osteocytes [39,40]
 Bone marrow mesenchymal stem cells 5-aza-2’-deoxycytidine Cardiomyocytes [45,58]
 Bone marrow mesenchymal stem cells 5-aza-2’-deoxycytidine; trichostatin A Osteocytes; chondrocytes [41]
 Bone marrow mesenchymal stem cells 5-aza-2’-deoxycytidine; trichostatin A Neural-like cells [42]
 Bone marrow mesenchymal stem cells Sodium butyrate Osteocytes [59]
 Cardiac progenitor stem cells 5-aza-2’-deoxycytidine Cardiomyocytes [60]
 Neural progenitor stem cells Trichostatin A Neuronal cells [61]
 Neural progenitor stem cells Valproic acid Neuronal cells [62]
 Umbilical cord mesenchymal stem cells 5-aza-2’-deoxycytidine Cardiomyocytes [63]
Pluripotent stem cells   
 Embryonic stem cells 5-aza-2’-deoxycytidine Cardiomyocytes [64,65]
 Embryonic stem cells 5-aza-2’-deoxycytidine Endothelial cells [66]
 Embryonic stem cells Trichostatin A Cardiomyocytes [67,68]
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there is evidence that HDAC inhibitors and DNA 
demethylating agents are useful for enhancing iPS 
reprogramming [50,51]. A prerequisite in reprogramming 
of iPS from somatic cells is that some stemness-related 
promoters become demethylated. How might this 
demethylation be achieved? It could be done through a 
DNA repair mechanism [52,53] or by the recent dis-
covery of TET proteins, a group of enzymes that convert 
methylated 5-methylcytosine to 5-hydroxy methyl-
cytosine [54]. Although experimental models for repro-
gram ming have generated a considerable amount of 
infor mation, many questions remain. How diff erent is the 
epigenetic regulation of pluripotent and multipotent 
cells? Does CpG methylation underpin self-renewal in 
adult stem cells, as it does in ES cells? Do epigenetic 
marks defi ne the lineage potential of an adult stem cell? Is 
it possible to revert the diff erentiation program by 
manipu lating the epigenome? How safe is this reversion? 
Th e recent discovery that nearly one quarter of all 
methylation identifi ed in ES cells was found in a non-CG 
context [55] suggests that the genomic context must also 
be addressed. Do ES cells use a diff erent methylation 
mechanism for gene regulation? Furthermore, long-term 
in vitro culture of adult stem cells, a prerequisite for 
large-scale expansion previous to implantation with 
thera peutic purposes, showed specifi c alterations of CpG 
island methylatyion [56]. As a consequence, it is 
necessary to optimize and standardize the experimental 
protocols used for in vitro expansion which minimize 
epigenetic-related instability. In conclusion, although 
manipulation of epigenetic activity might be an interest-
ing means of generating populations of specifi c cell types, 
additional epigenetic research on the understanding of 
stem cell biology must be done before they can be used as 
diff erentiation agents in stem cell-based therapies.
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